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Editorial
Colorectal cancer prevention in Brazil - where are we?
Prevenção do câncer colorretal no Brasil - onde estamos?
Colorectal cancer (CRC) has high incidence and mortality 
in our country. According to estimates of incidence for 2012 
from the National Cancer Institute (INCA),1 14,180 new cases 
of cancer of the colon and rectum are expected in men and 
15,960 in women, corresponding to an estimated risk of 15 
new cases per 100,000 men and 16 per 100,000 women. Exclu-
ding the non-melanoma skin tumors, cancer of the colon and 
rectum is the third most frequent in both genders in Brazil 
and the second in the Southeast region, surpassing lung can-
cer in men and cervical cancer in women. 
Although it originates from benign lesions in most cases and 
the fact that it has a biological behavior characterized by slow 
growth, it has a high mortality rate. Thus, CRC has characteristics 
that justify performing preventive campaigns: high incidence 
and mortality, as well as favorable prognosis in the early stages.
The incidence has increased in recent years, which beco-
mes evident in our daily clinical activities. Patients receive the 
diagnosis with great surprise and total unawareness about 
the disease, some with evident risk factors. We continue to 
identify a worsening situation, which fi lls our outpatient cli-
nics and operating rooms, consumes millions of reais in tre-
atment and follow-up and brings great suffering for the pa-
tients and their families. 
Prevention is effective and can reduce mortality by 60%.2,3 
Strategies of CRC prevention and early diagnosis were intro-
duced in the 1970s and 1980s, after fi nding that the use of fe-
cal tests was feasible and effective. Randomized trials showed 
a reduction in the incidence of mortality, supporting their re-
commendation as an effective method for early diagnosis.4,5 
Considering this situation, we must ask ourselves why gover-
nmental public health measures to fi ght colorectal cancer are 
not present in Brazil, unlike other countries. 
In the United States, Societies and Institutes responsible 
for cancer treatment, prevention and registry show epidemio-
logical data, and also the impact from interventions such as 
screening and treatment. They have identifi ed, for instance, 
that the slight decline in the incidence of colorectal cancer 
in the country can be attributed to the large number of colo-
noscopies performed, around 40 million/year, and to a lesser 
extent, to behavioral changes or more effective therapies. In 
Great Britain, in the last 30 years, the estimated incidence for 
the development of colorectal cancer increased from 3.5% to 
6.9%.6 Thus, since 2006, they have implemented a prevention 
program to test occult blood every two years, intended for in-
dividuals older than 60 years, aiming to reduce mortality by 
16%.  
However, even in developed countries, there are diffi cul-
ties in implementing effective and permanent campaigns 
at population level, which can be attributed to the complex 
logistics, lack of access to endoscopic tests and high costs. 
In Brazil, in recent years, we have identifi ed a growing de-
mand for preventive screening in colonoscopy services, whe-
ther by medical indication or spontaneous request, demons-
trating awareness of the patients on the subject, albeit on a 
small scale. However, it can be assumed that only a small por-
tion of the population benefi ts from this type of prevention. 
One should also consider that the poor access to high quality 
medical care in the public system, as well as the existence 
of conditions that negatively impact on public health, such 
as poor sanitation, makes the implementation of systematic 
campaigns by the government to prevent the most common 
malignancies a very diffi cult task.
Thus, campaigns arising from the private sector have 
emerged in recent years with the intention of fi lling this gap, 
with the creation of the Brazilian Association of Intestinal 
Cancer Prevention (ABRAPRECI) and the Colorectal Cancer 
Prevention and Screening Program carried out at the Hospital 
Alemão Oswaldo Cruz in São Paulo. 
In UNICAMP, a CRC screening and prevention program was 
implemented in 2011 in the Zeferino Vaz Campus, aiming to 
include employees, students and faculty aged > 50 years, with 
an estimated population of 5,000 people. Conceived by the Co-
loproctology Unit and implemented by the Community Health 
Center (CECOM), the program is based on guidance lectures, 
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providing occult blood testing, colonoscopy and surgery when 
necessary and monitoring of participants. Initial results sho-
wed adherence of 50% in 2012 and provided information to the 
general public as a secondary outcome, which extrapolated the 
limits of the campus. The acquired experience has enabled ad-
justments that allowed the identification of reasons for non-
-compliance, as well as the implemention of measures that 
enabled effective monitoring and guidance in positive cases. 
The continental size of Brazil, with its vast regional diffe-
rences and structural deficiencies, makes it impossible, at le-
ast currently, to establish a national campaign, but experien-
ce from the private sector or government agencies such as 
UNICAMP has shown that these programs are feasible in our 
country and should encourage similar regional campaigns. 
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